Aneurysmal Subarachnoid Hemorrhage Clinical Trial
— EARLYDRAINOfficial title:
EARLYdrain - Prospective Outcome Study of Early Lumbar Drainage in Aneurysmal Subarachnoid Hemorrhage
Verified date | February 2017 |
Source | Charite University, Berlin, Germany |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The intention of the study is to investigate whether drainage of cerebral spinal fluid via a lumbar route ("Tuohy-drain") will improve outcome after intracranial aneurysmal subarachnoid hemorrhage (SAH).
Status | Completed |
Enrollment | 300 |
Est. completion date | September 2016 |
Est. primary completion date | August 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Age of 18 years or older - First aneurysmal SAH - Pre-morbid modified Rankin Scale score 0 or 1 - Aneurysm treatment performed in the first 48 hours after the initial hemorrhage. - Informed consent by the patient or his/her legal representative. In case neither the patient is capable of giving informed consent nor a legal representative is available, informed consent can be given by an independent physician neither involved in the patient´s treatment nor the trial (for specification see below) Exclusion Criteria: - Subarachnoid hemorrhage of other than aneurysmal origin - No hemorrhage visible on initial CCT scan (Fisher Grade I) - Pregnancy - Concurrent participation in another interventional trial (participation in an observational trial is allowed) - Life expectancy less than 1 year for other reasons than the actual SAH - Other concomitant severe disease that would confound with treatment - Other clear contraindication for treatment |
Country | Name | City | State |
---|---|---|---|
Germany | Charité University Medicine Department of Neurosurgery Campus Virchow Klinikum | Berlin |
Lead Sponsor | Collaborator |
---|---|
Charite University, Berlin, Germany |
Germany,
Klimo P Jr, Kestle JR, MacDonald JD, Schmidt RH. Marked reduction of cerebral vasospasm with lumbar drainage of cerebrospinal fluid after subarachnoid hemorrhage. J Neurosurg. 2004 Feb;100(2):215-24. — View Citation
Kwon OY, Kim YJ, Kim YJ, Cho CS, Lee SK, Cho MK. The Utility and Benefits of External Lumbar CSF Drainage after Endovascular Coiling on Aneurysmal Subarachnoid Hemorrhage. J Korean Neurosurg Soc. 2008 Jun;43(6):281-7. doi: 10.3340/jkns.2008.43.6.281. — View Citation
Tuettenberg J, Czabanka M, Horn P, Woitzik J, Barth M, Thomé C, Vajkoczy P, Schmiedek P, Muench E. Clinical evaluation of the safety and efficacy of lumbar cerebrospinal fluid drainage for the treatment of refractory increased intracranial pressure. J Neurosurg. 2009 Jun;110(6):1200-8. doi: 10.3171/2008.10.JNS08293. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Disability in Lumbar drainage group (LD) vs. disability in control group (No-LD) | Disability is assessed by the modified Rankin Scale, dichotomized at a score of 0 to 2 versus 3 to 6 (6=death).Assessment is performed by a blinded investigator of the local study center by personal visit. Alternatively, a telephone questionnaire is suitable for outcome assessment of the modified Rankin Scale (13). Outcome assessment is planned to be done on the whole dataset as well as in preplanned stratified subsets (i.e. for example clinical SAH grade according to the Hunt&Hess scale 1-2 vs. 3-5 (14), CT grading according to Fisher I-III vs. IV (15)). | 6 months after SAH | |
Secondary | mortality | 6 months after SAH | ||
Secondary | Modified Rankin scale (mRS) score as continuous variable | 6 months after SAH | ||
Secondary | Angiographically determined vasospasm | Vasospasm here is defined as a caliber reduction by 33% or more on day 7-9 compared to the initial digital subtraction angiography. | once between day 7 to 9 after SAH | |
Secondary | Vasospastic infarction | last CT-scan during hospital stay, an expected average of 4 weeks | ||
Secondary | Expression of clinical delayed neurological deficit | day 1-14 after SAH | ||
Secondary | Transcranial duplex ultrasound measured flow velocity in both middle cerebral arteries | TCD-measured mean flow velocity in both MCA is determined daily at a depth of 50-60 mm. | daily during hospital stay of the patient | |
Secondary | Early mortality | Time span of initial hospital treatment after SAH, an expected average of 4 weeks | ||
Secondary | Rate of CSF shunt insertion in the first six months | First 6 months after SAH | ||
Secondary | Presence of CSF infection | Infection in this case is defined by the modified criteria for device-associated (CDC) meningitis (treatment required on either positive culture, or elevated cell count, red cell/ white cell ratio, increased lactate and/or decreased glucose) | First 14 days after SAH |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03209830 -
Pharmaceutical Treatment of Fatigue After Aneurysmal Subarachnoid Hemorrhage
|
Phase 2 | |
Completed |
NCT05131295 -
Dapsone Use in Patients With Aneurysmal Subarachnoid Hemorrhage.
|
Phase 3 | |
Recruiting |
NCT04583163 -
Variability in Transcranial Doppler Technique in Neuro-Critical Care Patients
|
||
Not yet recruiting |
NCT03271697 -
Astragalus Membranaceus on Aneurysmal Subarachnoid Hemorrhage
|
Phase 2/Phase 3 | |
Recruiting |
NCT01098890 -
Intraventricular Tissue Plasminogen Activator (tPA) in the Management of Aneurysmal Subarachnoid Hemorrhage
|
Phase 2 | |
Completed |
NCT00692744 -
Quality of Life in Elderly After Aneurysmal Subarachnoid Hemorrhage (SAH)
|
N/A | |
Active, not recruiting |
NCT05738083 -
Prediction Models for Complications, Disability, and Death in Patients With Aneurysmal Subarachnoid Hemorrhage
|
||
Completed |
NCT03754335 -
SubArachnoid Hemorrhage HEadache Treated by Lumbar Puncture
|
N/A | |
Completed |
NCT06076590 -
Impact of Multiple Electrolytes Injection Ⅱ and Saline on Hyperchloremia in Patients With Aneurysmal Subarachnoid Hemorrhage:a Pilot Study
|
Phase 4 | |
Recruiting |
NCT04548401 -
Effect of Antiplatelet Therapy on Cognition After Aneurysmal Subarachnoid Hemorrhage
|
||
Terminated |
NCT04148105 -
Cilostazol and Nimodipine Combined Therapy After Aneurysmal Subarachnoid Hemorrhage (aSAH)
|
Phase 4 | |
Recruiting |
NCT06329635 -
Treatment of Vasospasm of Aneurysmal Subarachnoid Hemorrhage With Intrathecal Nicardipine - FAST-IT Trial
|
N/A | |
Recruiting |
NCT02129413 -
Safety Study of Carotid Body Neurostimulation to Treat Cerebral Vasospasm
|
N/A | |
Terminated |
NCT00487461 -
Use of Simvastatin for the Prevention of Vasospasm in Aneurysmal Subarachnoid Hemorrhage
|
N/A | |
Recruiting |
NCT06288659 -
aSAH Treatment Based on Intraventricular ICP Monitoring: A Prospective, Multicenter, Randomized and Controlled Trial
|
N/A | |
Recruiting |
NCT05974111 -
COAgulation Disorders in Ischaemic and Haemorrhagic Stroke
|
||
Recruiting |
NCT03706768 -
Degradation of the Glycocalyx in Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage
|
N/A | |
Recruiting |
NCT06284642 -
Early Lumbar Drainage Combined With Intrathecal Urokinase Injection for Treatment of Severe Aneurysmal SAH (LD-ITUK)
|
Phase 4 | |
Recruiting |
NCT01773200 -
Prognostic Value of Circulating Endothelial Progenitor Cells in Aneurysmal Subarachnoid Hemorrhage
|
N/A | |
Completed |
NCT02026596 -
SpareBrain - Mechanisms and Prevention of Secondary Brain Injury in Subarachnoid Haemorrhage
|
N/A |